| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 193.03 | 3.1% |
| Total Income | 197.68 | 3.1% |
| Expenditure | 147.45 | 2.5% |
| PBT | 50.23 | 5.0% |
| Net Profit | 38.29 | 77.5% |
| OPM | 29.93% | 0.90pp |
| NPM | 19.37% | 8.12pp |
| EPS | 7.35 | 76.3% |
Thyrocare Technologies Ltd Reports Q1FY26 Revenue of INR 193.03 Cr with 23% YoY Growth
23 Jul 2025 · 23 Jul 2025, 03:57 pm
Summary
Thyrocare Technologies Limited, a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2025. The company saw a YoY increase of 23% in consolidated revenue, driven by a 25% growth in Pathology and a 6% growth in Radiology. Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase. Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%. Consolidated EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%.
Key Highlights
- 1
Consolidated revenue saw a YoY increase of 23%
- 2
Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY
- 3
Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase
- 4
Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%
- 5
Consolidated EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%
- 6
Opened New Labs in Bhagalpur, Kashmir and Roorkee
Management Comments
Not specified
Thyrocare Tests you can trust
Informational and educational content only. Not investment advice.